GLPwatch
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
NCT07301437 · Not yet recruiting
Last updated 2026-05-28This study tested whether the medication liraglutide, alone or combined with orlistat, helps adults who are overweight or obese lose weight.
Status Not yet recruiting Approved but enrollment has not started.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 120 people Planned (estimated).
Who can join Ages 18–65 · all sexes
Timeline Started 2026-05 · est. completion 2027-08
What this study is testing ClinicalTrials.gov NCT07301437 ↗
Description as written by the study sponsor.
To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
Treatments tested
- liraglutide monotherapy Drug
liraglutide monotherapy
- liraglutide combined with orlistat Drug
combination therapy
| Main thing measured | weight loss |
|---|---|
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Conditions studied | Overweight and Obese Adults |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07301437 ↗